Stock Analysis on Net
Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

Analysis of Revenues

Microsoft Excel

Revenues as Reported

Amgen Inc., income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Human therapeutics 32,026 26,910 24,801 24,297 24,240
Product sales 32,026 26,910 24,801 24,297 24,240
Other revenues 1,398 1,280 1,522 1,682 1,184
Revenues 33,424 28,190 26,323 25,979 25,424

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
Revenues Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Amgen Inc. revenues increased from 2022 to 2023 and from 2023 to 2024.